Cargando…
Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment
Previous gene therapy trials for X-linked chronic granulomatous disease (X-CGD) lacked long-term engraftment of corrected hematopoietic stem and progenitor cells (HSPCs). Chronic inflammation and high levels of interleukin-1 beta (IL1B) might have caused aberrant cell cycling in X-CGD HSPCs with a c...
Autores principales: | Klatt, Denise, Ha, Teng-Cheong, Schinke, Maximilian, Selich, Anton, Lieske, Anna, Dahlke, Julia, Morgan, Michael, Maetzig, Tobias, Schambach, Axel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600420/ https://www.ncbi.nlm.nih.gov/pubmed/33003308 http://dx.doi.org/10.3390/cells9102194 |
Ejemplares similares
-
Sequence determinants of improved CRISPR sgRNA design
por: Xu, Han, et al.
Publicado: (2015) -
TGFβ Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy
por: Fleischauer, Jenni, et al.
Publicado: (2023) -
A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML
por: Hassan, Jacob Jalil, et al.
Publicado: (2021) -
sgRNA-PSM: Predict sgRNAs On-Target Activity Based on Position-Specific Mismatch
por: Liu, Bin, et al.
Publicado: (2020) -
Synthesis of an arrayed sgRNA library targeting the human genome
por: Schmidt, Tobias, et al.
Publicado: (2015)